YUHAN CORPORATION
Financials
Valuation Metrics
YUHAN CORPORATION's Market Cap is ₩5.7T. At end of 2025 it was ₩8.4T. Ranked #98 of 2,421 in KR market (top 4%), #92 of 781 on KOSPI (top 12%), #7 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.70T KRW | KR#98/2,421 Sec#7/231 |
| Revenue | 2.28T KRW | KR#234/2,421 Sec#4/231 |
| Net Income | 222.72B KRW | KR#133/2,421 Sec#5/231 |
| Total Assets | 3.33T KRW | KR#225/2,421 Sec#6/231 |
| Net Assets | 2.47T KRW | KR#156/2,421 Sec#4/231 |
| Employees | 2,117 | KR#133/2,421 Sec#6/231 |
| Value | ||
| P/E | 25.59x | KR#1,258/2,421 Sec#74/231 |
| P/B | 2.31x | KR#2,008/2,421 Sec#151/231 |
| PEG | 0.14x | KR#487/2,421 Sec#28/231 |
| P/S | 2.50x | KR#1,915/2,421 Sec#111/231 |
| EV/EBITDA | 45.42x | KR#1,322/2,421 Sec#83/231 |
| FCF Yield | 0.12% | KR#1,209/2,421 Sec#91/231 |
| Profitability | ||
| ROE | 9.01% | KR#698/2,421 Sec#49/231 |
| ROA | 6.69% | KR#551/2,421 Sec#44/231 |
| Op. Margin | 5.42% | KR#912/2,421 Sec#68/231 |
| Revenue Growth | 5.40% | KR#1,174/2,421 Sec#115/231 |
| Earnings Growth | 178.66% | KR#261/2,421 Sec#16/231 |
| Financial Health | ||
| Debt Ratio | 34.77% | KR#687/2,421 Sec#83/231 |
| Total Debt | 349.53B KRW | KR#370/2,421 Sec#18/231 |
| FCF | 6.63B KRW | KR#832/2,421 Sec#54/231 |
| Cash | 427.95B KRW | KR#158/2,421 Sec#2/231 |
| Current Ratio | 2.27x | KR#767/2,421 Sec#91/231 |
| Net Debt/EBITDA | -0.63x | KR#462/2,421 Sec#26/231 |
| Dividend | ||
| Div. Yield | 0.79% | KR#1,175/2,421 Sec#71/231 |
| Div. Growth | 20.00% | KR#437/2,421 Sec#23/231 |
| Performance | ||
| 1Y Return | -34.70% | KR#1,701/2,421 Sec#137/231 |
| 1M Return | -4.02% | KR#1,704/2,421 Sec#134/231 |
| From 52W High | -40.87% | KR#964/2,421 Sec#68/231 |
| 1Y MDD | -46.88% | KR#851/2,421 Sec#70/231 |
| Trading | ||
| Volume | 201,992 shares | KR#487/2,421 Sec#32/231 |
| Trading Value | 15.45B KRW | KR#198/2,421 Sec#14/231 |
| Foreign Own. | 21.26% | KR#209/2,421 Sec#9/231 |
| Per Share | ||
| EPS | 2,985 KRW | KR#342/2,421 Sec#22/231 |
| BPS | 33,117 KRW | KR#343/2,421 Sec#22/231 |
Company Info
Established in 1926 and listed on the securities market in 1962, the company is a leading pharmaceutical firm, with 14 companies under its umbrella, including a subsidiary slated for KOSDAQ listing in 2025. Its primary business is the manufacturing and sale of pharmaceuticals and chemical products, including key products like Leclaza. The company is building an innovative network by adopting AI and big data for new drug development, collaborating with global pharmaceutical companies, and conducting joint R&D with bio-ventures and universities. The company is headquartered in Dongjak-gu, Seoul.